Article ; Online: The old but new: Can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?
2020 Volume 142, Page(s) 109743
Abstract: Currently, our world is facing the 2019 Novel Coronavirus (COVID-19) outbreak and tremendous efforts are made for developing drugs to treat and vaccines to prevent the disease. At present, there is no specific antiviral drug or vaccine for COVID-19. The ... ...
| Abstract | Currently, our world is facing the 2019 Novel Coronavirus (COVID-19) outbreak and tremendous efforts are made for developing drugs to treat and vaccines to prevent the disease. At present, there is no specific antiviral drug or vaccine for COVID-19. The pathogenic infectivity of the virus requires the S1 subunit of the spike (S) protein to bind the host cell receptor, angiontensin converting enzyme (ACE2). While the binding to host cell receptor is the first step of infection, the entrance of the virus into the cell needs the cleavage of S1-S2 subunits to expose S2 for fusion to cell membrane via host proteases including cathepsins, cell surface transmembrane protease/serine (TMPRSS) proteases, furin, trypsin and factor Xa. Previous in vitro studies have shown that factor Xa inhibition can decrease viral infectivity. We suppose that host cell proteases including furin (as expressed highly in lungs), factor Xa and cathepsin are possible targets to decrease viral burden, therefore unfractioned heparin and low molecular weight heparin-LMWH (specifically dalteparin and tinzaparin for their anti inflammatory action) can be potential inhibitors of multiple endoproteases involved in virus infectivity. Our hypothesis needs to be tested in in vitro and clinical studies, however as we are in an urgent situation as the burden of SARS-CoV2 is increasing all around the world, we recommend the usage of unfractioned heparin or LMWH in intensive care unit (ICU) and non-ICU hospitalized patients with the risk-benefit judgement of the clinician. Whether our hypothesis is clinically applicable and successful in decreasing viral infection will be evaluated for further studies. |
|---|---|
| MeSH term(s) | Betacoronavirus/drug effects ; COVID-19 ; Coronavirus Infections/blood ; Coronavirus Infections/drug therapy ; Drug Administration Schedule ; Factor Xa/metabolism ; Heparin/pharmacology ; Heparin, Low-Molecular-Weight/pharmacology ; Humans ; Models, Theoretical ; Pandemics ; Pneumonia, Viral/blood ; Pneumonia, Viral/drug therapy ; Protease Inhibitors/pharmacology ; Protein Binding ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/chemistry |
| Chemical Substances | Heparin, Low-Molecular-Weight ; Protease Inhibitors ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; Heparin (9005-49-6) ; Factor Xa (EC 3.4.21.6) |
| Keywords | covid19 |
| Language | English |
| Publishing date | 2020-04-20 |
| Publishing country | United States |
| Document type | Journal Article |
| ZDB-ID | 193145-3 |
| ISSN | 1532-2777 ; 0306-9877 |
| ISSN (online) | 1532-2777 |
| ISSN | 0306-9877 |
| DOI | 10.1016/j.mehy.2020.109743 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Zs.A 1132: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.